Guangzhou, China and Berlin, Germany (PRWEB) February 17, 2015
Plexera Biotechnology Ltd., exclusively representing Plexera® LLC, and JPT Peptide Technologies GmbH, a wholly-owned subsidiary of BioNTech AG, today announced finalization of a distribution and collaboration agreement.
The agreement provides for distribution of JPT’s innovative peptide-based products and services to the Chinese immunotherapy, vaccine and proteomics markets. Furthermore, the partnership promotes the development of peptide-based applications on the PlexArray® HT, Plexera’s high-throughput proteomics screening platform.
“This partnership represents a strategic cornerstone in our continued efforts to address all major global markets with our broad portfolio of proprietary and high quality products for the discovery of novel biomarkers and the development of immunotherapies and vaccines” said Holger Wenschuh, CEO of JPT. He added, “Plexera proved to be the ideal partner for our goals as they not only understand the challenge of explaining complex products for high level biomedical applications but also possess a decade long track record of effectively approaching the Chinese market and its opportunities.”
Jingsong Zhu, CEO of Plexera commented: “JPT’s high performance peptide tools and services for applications in rapidly developing biotechnology arenas represent an optimal complement to our own functional proteomics solutions, including our unique PlexArray® Technology. We trust that Chinese customers will appreciate the joint efforts to make these products readily available.”
Plexera LLC provides advanced SPRi-based solutions for a variety of chemical and biological appli-cations requiring high-throughput screening and analysis of biomolecular interactions. The company is based in Woodinville, WA (USA) and has laboratory facilities at the Institute for Systems Biology in Seattle. Plexera is exclusively represented in China by Guangzhou Gaotong Biotechnology Co.,Ltd. for sales, marketing, and application development and Pu Rui Tong Liang Co.,Ltd. in Beijing for sales, marketing, and product development. In Japan the company is exclusively represented by Cell Produce Co., Ltd.
About JPT Peptide Technologies GmbH
JPT Peptide Technologies GmbH, a wholly owned subsidiary of BioNTech AG (Mainz, Germany), is a DIN ISO 9001:2008 certified research and development partner and innovative service provider for peptide related projects. JPT’s key technologies SPOTTM – for ultra-high-throughput peptide synthesis and screening, PepStarTM – for high-content peptide microarrays, PepTrackTM - for flexible peptide library assembly, PepMixTM – for antigen specific T-cell stimulation using peptide pools, and SpikeTideTM – for protein biomarker quantification accelerate research and development in areas such as immune monitoring, vaccine development, peptide biomarker discovery, peptide lead identification and optimization, enzyme profiling and proteomics.
For further information please contact:
JPT Peptide Technologies GmbH